Tags

Type your tag names separated by a space and hit enter

Assessment of Promoter Hypermethylation and Expression Profile of P14ARF and MDM2 Genes in Patients With Pterygium.
Eye Contact Lens. 2016 Jan; 42(1):e4-7.EC

Abstract

BACKGROUND

Pterygium is a fairly general condition in many regions of the world. The cause of this abnormality is still ambiguous. However, recent findings suggest that pterygium is a benign progressive tissue and not a degenerative disorder. The main goal of our study was to investigate the effects of P14 and MDM2 promoter methylation on the risk of pterygium.

MATERIALS AND METHODS

In this study, the DNA of 81 primary pterygium and 75 normal conjunctiva tissues was extracted and modified for the assessment of methylation of P14 and MDM2 promoters by methylation-specific polymerase chain reaction (MSP). We also estimated the mRNA expression levels of these genes in 23 pterygium and 18 normal conjunctiva tissue samples using real-time quantitative reverse transcriptase polymerase chain reaction.

RESULTS

The frequency of methylation for P14 was 92.6% for cases and 97.3% for controls. MDM2 gene methylation at the promoter site was 39.5% and 72.0% for pterygium and normal conjunctiva tissues, respectively. So statistically, a significant relationship between MDM2 gene promoter methylation and the risk of disease was found (odds ratio=5.3; 95% confidence limit, 2.6-10.8; P<0.0001). In addition, the expression of MDM2 gene has increased in pterygium (1.371548±0.6727) in comparison with conjunctiva tissues as control (1.20621±1.0) (P<0.05), but it was not significant for P14 gene.

CONCLUSION

Our results have indicated that hypomethyaltion and overexpression of MDM2 gene take place in patients with the pterygium. To confirm the presented data, suggesting further studies with a larger sample size in various genetic populations.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Arish M
Department of Ophthalmology (M.A.), Al-Zahra Eye Hospital, Zahedan University of Medical Sciences, Zahedan, Iran; and Department of Biology (D.M.K-T., M.H.S., R.P.), University of Sistan and Baluchestan, Zahedan, Iran.
Kordi-Tamandani DM
No affiliation info available
Sangterash MH
No affiliation info available
Poyandeh R
No affiliation info available

MeSH

AdultAgedCase-Control StudiesConjunctivaDNA MethylationFemaleHumansMaleMiddle AgedPolymerase Chain ReactionPromoter Regions, GeneticProto-Oncogene Proteins c-mdm2PterygiumRNA, MessengerTumor Suppressor Protein p14ARF

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26020483

Citation

Arish, Mohammad, et al. "Assessment of Promoter Hypermethylation and Expression Profile of P14ARF and MDM2 Genes in Patients With Pterygium." Eye & Contact Lens, vol. 42, no. 1, 2016, pp. e4-7.
Arish M, Kordi-Tamandani DM, Sangterash MH, et al. Assessment of Promoter Hypermethylation and Expression Profile of P14ARF and MDM2 Genes in Patients With Pterygium. Eye Contact Lens. 2016;42(1):e4-7.
Arish, M., Kordi-Tamandani, D. M., Sangterash, M. H., & Poyandeh, R. (2016). Assessment of Promoter Hypermethylation and Expression Profile of P14ARF and MDM2 Genes in Patients With Pterygium. Eye & Contact Lens, 42(1), e4-7. https://doi.org/10.1097/ICL.0000000000000126
Arish M, et al. Assessment of Promoter Hypermethylation and Expression Profile of P14ARF and MDM2 Genes in Patients With Pterygium. Eye Contact Lens. 2016;42(1):e4-7. PubMed PMID: 26020483.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Assessment of Promoter Hypermethylation and Expression Profile of P14ARF and MDM2 Genes in Patients With Pterygium. AU - Arish,Mohammad, AU - Kordi-Tamandani,Dor Mohammad, AU - Sangterash,Mohammad Hussein, AU - Poyandeh,Robab, PY - 2015/5/29/entrez PY - 2015/5/29/pubmed PY - 2016/9/13/medline SP - e4 EP - 7 JF - Eye & contact lens JO - Eye Contact Lens VL - 42 IS - 1 N2 - BACKGROUND: Pterygium is a fairly general condition in many regions of the world. The cause of this abnormality is still ambiguous. However, recent findings suggest that pterygium is a benign progressive tissue and not a degenerative disorder. The main goal of our study was to investigate the effects of P14 and MDM2 promoter methylation on the risk of pterygium. MATERIALS AND METHODS: In this study, the DNA of 81 primary pterygium and 75 normal conjunctiva tissues was extracted and modified for the assessment of methylation of P14 and MDM2 promoters by methylation-specific polymerase chain reaction (MSP). We also estimated the mRNA expression levels of these genes in 23 pterygium and 18 normal conjunctiva tissue samples using real-time quantitative reverse transcriptase polymerase chain reaction. RESULTS: The frequency of methylation for P14 was 92.6% for cases and 97.3% for controls. MDM2 gene methylation at the promoter site was 39.5% and 72.0% for pterygium and normal conjunctiva tissues, respectively. So statistically, a significant relationship between MDM2 gene promoter methylation and the risk of disease was found (odds ratio=5.3; 95% confidence limit, 2.6-10.8; P<0.0001). In addition, the expression of MDM2 gene has increased in pterygium (1.371548±0.6727) in comparison with conjunctiva tissues as control (1.20621±1.0) (P<0.05), but it was not significant for P14 gene. CONCLUSION: Our results have indicated that hypomethyaltion and overexpression of MDM2 gene take place in patients with the pterygium. To confirm the presented data, suggesting further studies with a larger sample size in various genetic populations. SN - 1542-233X UR - https://www.unboundmedicine.com/medline/citation/26020483/Assessment_of_Promoter_Hypermethylation_and_Expression_Profile_of_P14ARF_and_MDM2_Genes_in_Patients_With_Pterygium L2 - https://doi.org/10.1097/ICL.0000000000000126 DB - PRIME DP - Unbound Medicine ER -